AstraZeneca PLC (STO:AZN)
1,611.00
0.00 (0.00%)
Oct 7, 2025, 5:29 PM CET
AstraZeneca Revenue
AstraZeneca had revenue of $14.46B USD in the quarter ending June 30, 2025, with 11.74% growth. This brings the company's revenue in the last twelve months to $56.50B, up 15.00% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
$56.50B
Revenue Growth
+15.00%
P/S Ratio
4.66
Revenue / Employee
$599.16K
Employees
94,300
Market Cap
2,501.22B SEK
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Swedish Orphan Biovitrum AB | 26.97B |
Sectra AB | 3.37B |
Getinge AB | 35.50B |
Camurus AB | 2.27B |
Medicover AB | 25.22B |
Asker Healthcare Group AB | 15.88B |
BioArctic AB | 1.86B |
AddLife AB | 10.44B |
AstraZeneca News
- 8 hours ago - AstraZeneca (AZN) Reports Success in Phase 3 Hypertension Trial - GuruFocus
- 8 hours ago - AZN: Baxdrostat Shows Promising Results in Phase III Trial - GuruFocus
- 9 hours ago - AstraZeneca succeeds in late-stage trial for blood pressure therapy - Seeking Alpha
- 10 hours ago - Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension - Business Wire
- 14 hours ago - AZN : Baxdrostat Meets Primary Endpoint In Phase III Trial For Treatment-Resistant Hypertension - Nasdaq
- 14 hours ago - AstraZeneca's Baxdrostat meets main goal in high blood pressure study - Reuters
- 1 day ago - AstraZeneca (AZN) Signs $555 Million AI Agreement with Algen to Develop Therapies - GuruFocus
- 1 day ago - AstraZeneca (AZN) Achieves Key Milestones in Breast Cancer Treatment Study - GuruFocus